RNS Number: 1394 S RUA Life Sciences PLC 06 July 2020. TR-1: Standard form for notification of major holdings. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9059 R RUA Life Sciences PLC 03 July 2020. RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer, announces that it expects to report its audited final results for the year ended 31 March 2020 on 13 July 2020.. Bill Brown, Chairman Tel: +44...
RNS Number: 7665 R RUA Life Sciences PLC 02 July 2020. RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer, is pleased to announce completion of the purchase of a factory unit and associated cleanroom facilities at Skye Road Prestwick..
AorTech International Plc (AOR.L) Announced that the change of its name, and rebranding of all group businesses, under the RUA brand has taken effect. Accordingly, it is expected that trading on AIM in the company's ordinary shares under the new name, RUA Life Sciences Plc and at the same time the company's TIDM would change to "RUA". #AOR
RNS Number: 1522 Q AorTech International PLC 17 June 2020. Change of name and rebranding. Further to its announcement of 31 March 2020, AorTech International Plc, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer, confirms that the change of its name, and...
RNS Number: 1712 P AorTech International PLC 08 June 2020 AorTech International plc. On 14 April 2020, AorTech announced that RUA had been notified by its largest customer that, due to US Government mandates to suspend all elective surgery in hospitals and surgical centres throughout the United States, it was temporarily unable to provide forecasts and...
AorTech International Plc (AOR.L) Announced that the United States Patent and Trademark Office has notified AorTech that its Application Number 15/995,050 will issue as Patent Number 10,676,560 entitled "BIOSTABLE POLYURETHANES" on 9 June 2020. #AOR
AorTech 111p £18m (AOR.L) The United States Patent and Trademark Office has notified AorTech that its Application Number 15/995,050 will issue as Patent Number 10,676,560 entitled "BIOSTABLE POLYURETHANES" on 9th June 2020. The invention relates to a biostable polyurethane or polyurea comprising: (a) a soft segment comprising a polysiloxane of the general formula disclosed in the Patent; and (b) greater than 0 and less than 40 wt % of a hard segment which is a reaction product of a diisocyanate and a linear difunctional chain extender, processes for their preparation and their use in the manufacture of biomaterials, implantable medical devices and polymeric heart valves. Bill Brown, Chairman of AorTech, said: "We are delighted that at the same time as major steps are being made in the development of our ElastEon™ enabled medical devices, our Intellectual Property portfolio relating to the ElastEon™ family of world class biostable polymers has been expanded further by the grant of this latest US patent. We currently anticipate reaching the significant milestone of commencing animal testing on the ElastEon™ sealed graft in the coming weeks." #AOR
RNS Number: 9873 N AorTech International PLC 27 May 2020 AorTech International plc. AorTech International plc, the holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer, is pleased to announce that the United States Patent and Trademark Office has notified...
AorTech 90p £14.6m (AOR.L) The holding company of a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer , announced that its subsidiary, RUA Medical Devices Limited, has successfully applied for, and been awarded, the maximum grant under a Scottish Government Covid-19 support scheme, The Pivotal Enterprise Resilience Fund (PERF) RUA Medical has received a total of £150,000 of Government grant support through the Pivotal Enterprise Resilience Fund administered by Scottish Enterprise. This grant will be used to support the working capital and ongoing business needs of RUA Medical. #AOR
RNS Number: 3975 N AorTech International PLC 20 May 2020 AorTech International plc. RUA Medical has received a total of £150,000 of Government grant support through the Pivotal Enterprise Resilience Fund administered by Scottish Enterprise. David Richmond, Group CEO of AorTech, stated: "We are delighted to have been supported with this award of £150,000...
AorTech 91p £14.7m (AOR.L) Trading update ahead of the publication of the Group’s audited final results for the financial year ended 31 March 2020, which are expected to be released in the second half of July 2020. Highlights: Growth in polymer licensing and royalty revenue from £463k to £490k Strong cash position of £2.0 million as at 31 March 2020 (2019: £2.4 million) Research and Development activities currently exceeding the Board’s expectations Integration of RUA Medical Devices Limited progressing to plan #AOR
#AOR In a well-received trading update Aortech have detailed their FY royalty and licensing revenues, cash balance and product developments. After many years in the making, the Elast-Eon tri-leaflet heart valve now appears to be ready for ‘prime time’.
AorTech International Plc (AOR.L) Announced that the Group's strategy remains to develop medical devices based upon the world class properties of AorTech's polymers whilst continuing to license the rights to those same polymers in non- competing areas. The polymer licensing business has continued to progress over the past year and revenues grew from the £463,000 reported last year to £490,000 in the year ended 31 March 2020. Investment in Research and Development increased over the year and, despite this additional investment, the company's year-end cash resources (including monies in solicitors client accounts for the completion of the acquisition of RUA Medical) stood at £1.98 million compared to £2.40 million at the same stage last year representing cash burn of a little over £400,000 during the year. Currently, Group cash balances stand at over £1.70 million. #AOR
RNS Number: 6925 M AorTech International PLC 13 May 2020 AorTech International plc. ·Growth in polymer licensing and royalty revenue from £463 k to £490 k. ·Strong cash position of £2.0 million as at 31 March 2020.
RNS Number: 5605 J AorTech International PLC 14 April 2020 14 April 2020. Late last week, RUA Medical Devices Limited, the Company's wholly-owned subsidiary, received communications from its largest customer that, due to US Government mandates to suspend all elective surgery in hospitals and surgical centres throughout the United States, it was temporarily...
RNS Number: 6185 I AorTech International PLC 02 April 2020 TR-1: S tandard form for notification of major holdings.. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4395 I AorTech International PLC 01 April 2020 1 April 2020. Further to its announcements made on 11, 25, 30 and 31 March 2020, AorTech, the licensor of the world's leading long-term implantable biostable polymer and developer of medical devices utilising the key properties of Elast-Eon TM, confirms that, following completion of the acquisition of...
#AOR ''RUA Medical now a done deal'' - AorTech’s £2.45m mainly stock, and cash acquisition of RUA Medical Devices Limited was approved by shareholders at the EGM on March 31. The transaction brings ‘in house’ AorTech’s partner in the development of its vascular products. The acquisition of RUA Medical also brings increased revenues for the combined company (which we now estimate at £2.2m for FY 2021) plus an enlarged management team with extensive medical device experience. We have taken the opportunity to run sensitivity analyses on the key valuation variables (which are predominantly the exit valuations of the vascular and heart valve products on acquisition). That suggests the stock-market is assigning very low probabilities of success for both products and/or extended timelines for their acquisition or licensing. Our fair value for the combined entity is unchanged at £101.2m or 689 pence per share, despite the recent market turmoil. - For full note click here:
RNS Number: 2039 I AorTech International PLC 31 March 2020 31 March 2020. AorTech International plc, the licensor of the world's long-term implantable biostable polymer and developer of medical devices utilising the key properties of Elast-Eon TM, announces that all resolutions put to Shareholders at the General Meeting held earlier today were duly passed.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    16.29M
Watchlist